Machaiah Madhrira, MD
Nephrology · Fort Worth, TXNPI 1043453293
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,420 of the $7,829 with a category attached, or 69.2%. 24 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 49.0% of the total. Reporting peaked in 2020 at $5,555 and has fallen 91.1% since, to $495 in 2025.
Across 105 payments — averaging $74.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$4K
- Amgen$3K
- Takeda Pharmaceuticals U.S.A., Inc.$310
- Vifor Pharma, Inc.$158
- Merck$99
- AstraZeneca$90
- plus $511 from 18 others
What the payments were for
- Speaking & faculty fees$5,42069%
- Food & beverage$2,38430%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 4 | $3,835 |
| Amgen(2 entities) | 46 | $2,827 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $310 |
| Vifor Pharma, Inc. | 3 | $158 |
| Merck | 5 | $99 |
| AstraZeneca(2 entities) | 5 | $90 |
| Bayer | 5 | $76 |
| Novo Nordisk | 4 | $65 |
| Veloxis Pharmaceuticals, Inc. | 2 | $61 |
| Travere Therapeutics, Inc. | 1 | $30 |
| Boehringer Ingelheim | 1 | $30 |
| GSK | 2 | $26 |
| OPKO Pharmaceuticals, LLC | 2 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Akebia Therapeutics Inc | 1 | $25 |
| Paratek Pharmaceuticals, Inc. | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
| Neos Therapeutics, LP | 1 | $18 |
| Cardinal Health 200 LLC | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
| Novartis | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,829 in reported general payments places this provider in the 85th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $70,757 |
| EliquisApixaban | 82 | $62,599 |
| XphozahTenapanor Hcl | 17 | $48,096 |
| JanuviaSitagliptin Phosphate | 61 | $47,677 |
| NulojixBelatacept | 13 | $24,560 |
| Cinacalcet Hcl | 96 | $23,965 |
| LokelmaSodium Zirconium Cyclosilicate | 26 | $21,222 |
| FarxigaDapagliflozin Propanediol | 17 | $14,028 |
| Valganciclovir Hcl | 94 | $12,258 |
| TradjentaLinagliptin | 12 | $11,690 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $8,338 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $8,254 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $6,469 |
| Nifedipine ErNifedipine | 193 | $6,452 |
| JardianceEmpagliflozin | 13 | $5,665 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $65 | $70,75767 claims |
| MerckJanuvia | $99 | $47,67761 claims |
| AstraZenecaLokelma, Farxiga | $90 | $35,25143 claims |
| E.r. Squibb & Sons, L.L.C.Nulojix | $11 | $24,56013 claims |
| Boehringer IngelheimTradjenta, Jardiance | $30 | $17,35525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Fort Worth
- Saravanan BalamuthusamyFort Worth$435K
- Sandeep ShoriFort Worth$195K
- Michael AragonFort Worth$138K
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.